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PURPOSE: Several clinical phenotypes including fetal hydrops, central conducting lymphatic anomaly or capillary malformations
with arteriovenous malformations 2 (CM-AVM2) have been associated with EPHB4 (Ephrin type B receptor 4) variants, demanding
new approaches for deciphering pathogenesis of novel variants of uncertain significance (VUS) identified in EPHB4, and for the
identification of differentiated disease mechanisms at the molecular level.
METHODS: Ten index cases with various phenotypes, either fetal hydrops, CM-AVM2, or peripheral lower limb lymphedema, whose
distinct clinical phenotypes are described in detail in this study, presented with a variant in EPHB4. In vitro functional studies were
performed to confirm pathogenicity.
RESULTS: Pathogenicity was demonstrated for six of the seven novel EPHB4 VUS investigated. A heterogeneity of molecular disease
mechanisms was identified, from loss of protein production or aberrant subcellular localization to total reduction of the
phosphorylation capability of the receptor. There was some phenotype–genotype correlation; however, previously unreported
intrafamilial overlapping phenotypes such as lymphatic-related fetal hydrops (LRFH) and CM-AVM2 in the same family were
observed.
CONCLUSION: This study highlights the usefulness of protein expression and subcellular localization studies to predict EPHB4
variant pathogenesis. Our accurate clinical phenotyping expands our interpretation of the Janus-faced spectrum of EPHB4-related
disorders, introducing the discovery of cases with overlapping phenotypes.
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INTRODUCTION
The EPHB4 gene encodes a receptor tyrosine kinase protein,
EPHB4, that binds to its ligand EphrinB2, to initiate complex
contact-dependent bidirectional signaling cascades, controlling
cellular fate during embryonic angiogenesis and essential cellular
processes such as adhesion, migration, and proliferation, in both
blood and lymphatic endothelial cells.1
We previously reported that monoallelic missense variants in
the intracellular tyrosine kinase domain of EPHB4 cause a form of
in utero primary lymphatic anomaly coined lymphatic-related fetal
hydrops with/without atrial septal defect (LRFH) (OMIM 617300).2
The study included two families (GLDUK and GLDNOR) with a
primarily lymphatic and venous phenotype, but with several
family members presenting with fetal hydrops and/or atrial septal
defects (ASD). Supporting evidence from mouse models lacking
Ephb4 expression during specific stages of development, or
genetically modified to alter only the Ephb4 dependent forward
signaling, show edema, blood filled lymphatic vessels with
defective collector valves, and lymphovenous valves,2,3 which
suggested the EPHB4-associated hydrops in the two families was
caused by a lymphatic-related fault. Li et al. identified an in-frame
insertion in EPHB4 in a family with a history of fetal hydrops and
lymphovenous dysfunction characterized by edema of the lower
extremities, venous stasis, and variable chylous effusions.4 This
work confirmed the important role of EPHB4 in the function and
development of the lymphatic system and the association of
EPHB4 variants with fetal hydrops of lymphovenous origin.
Other research groups have reported that loss-of-function,
monoallelic variants in the same gene can cause various vascular
pathologies. Under the umbrella of capillary malformation–
arteriovenous malformation 2 (CM-AVM2) (OMIM 618196) are
included several vascular pathologies such as isolated multifocal
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capillary malformations, telangiectasia, or high flow complex
arteriovenous malformations.5–8 Some patients with telangiectases
consistent with hereditary hemorrhagic telangiectasia (HHT) but
negative for the classical HHT-associated genes have been
positively screened for EPHB4 variants suggesting that the
spectrum of the CM-AVM2 phenotype should be expanded.9
EPHB4 variants have been detected in patients with cutaneous
telangiectases, initially suspected to have HHT, but negative for
variants in the classical HHT-associated genes. Upon review of
these cases regarding specific location, number, and appearance of
the telangiectases, they were noted to be distinct from those seen
in patients with HHT. The cutaneous telangiectases in these
patients with an EPHB4 variant had an earlier onset (childhood) and
were often innumerable in a given location. Some of the larger
lesions (labeled as capillary malformations [CMs]) were “haloed”
and occurred in locations (trunk and extremities) not typical of
HHT. These CMs probably represent larger dermal AVMs.
The increasing number of EPHB4 variants of uncertain
significance (VUS) identified through exome sequencing demands
rapid and effective tools to confirm pathogenicity to enable an
accurate genetic diagnosis. No clear phenotype–genotype corre-
lation associated with EPHB4 variants has yet been identified and
our understanding of the disease mechanism of the known causal
variants that could assist in clinical decision making is limited.
In this study we aimed to functionally investigate seven novel
EPHB4 VUS (from eight unreported index cases) associated with a
disease phenotype to predict their pathogenicity and attempted to
unravel the molecular disease mechanisms that could explain the
variable phenotypes. For comparison, three variants from previously
reported cases and three control variants selected from gnomAD
were also included in this investigation. We demonstrated the
pathogenic effect of six of the seven variants, showing a variety of
EPHB4-related disease mechanisms at a molecular level.
We present an increasing number of variable or overlapping
phenotypes associated with EPHB4 variants. These include a
dominant form of primary lymphedema without fetal hydrops,
ASD, or capillary malformation, and an intrafamilial overlapping
phenotype with capillary malformation (telangiectasia) and ASD,
with other members of the family presenting with fetal hydrops
but no telangiectasia, i.e., a dual (Janus-faced) phenotype. This
highlights that a detailed clinical evaluation of the affected
families and continuous follow-up are critical. Functional valida-
tion of the causative variants was undertaken, and various disease
mechanisms put forward. This knowledge will help in under-
standing any phenotype–genotype correlations, and aid clinical
practice.
MATERIALS AND METHODS
Patient selection, EPHB4 variant detection, and
lymphoscintigraphy
Ten index cases and affected family members with variants in EPHB4 were
included in the study. Two were previously described,2 and eight were
novel, unreported referrals. Of those, five cases were direct referrals from
clinicians, two were identified through the Prenatal Assessment of
Genomes and Exomes (PAGE) study,10 and one was identified through
GeneMatcher.11 See Supplementary Information, Supplementary Table 1,
and Supplementary Figs. 1–3 for detailed clinical information of the
recruited cases. EPHB4 variants were detected by next-generation
sequencing (NGS) in the respective molecular genetics services and
confirmed by Sanger sequencing.
Patients from the GLDUK, GLDNOR, and PL1 families underwent lower
limb lymphoscintigraphy, which was performed according to standard
local procedure by injecting radioactive isotope (technetium-99m-nano-
coll) into the web spaces between the toes.12,13 Images were taken at 15
minutes and 2 hours postinjection with a gamma camera. Quantification
figures 2 hours postinjection were calculated, where possible, as
percentage (%) of tracer retention within right and left foot, and tracer
uptake in the ilioinguinal nodes.
In silico analysis
The relative genomic and protein positions of EPHB4 reported here
correspond to the transcript EPHB4–001 (RefSeq: NM_004444, Ensembl:
ENST00000358173.3) and P54760 Uniprot protein accession ID. The
reported genomic coordinates refer to the GRCh38/hg38 human genome
reference. Putative changes in the gene structure and/or amino acid
sequence caused by the reported variants were retrieved from the
University of California–Santa Cruz (UCSC) Refgene database.14 Allele
frequencies (AF) were checked in gnomAD databases.15 Pathogenicity was
predicted by the Combined Annotation Dependent Depletion (CADD)
tool,16 MutationTaster,17 and PolyPhen-2.18 The protein model of EPHB4
was generated in R using the Bioconductor trackViewer package.19
Multiple sequence alignments of EPHB4 protein from different species
were performed using the T-Coffee tool.20
Site-directed mutagenesis of EPHB4 constructs
Fifty nanograms of the EPHB4 mammalian expression vector Myc-DDK-
tagged pCMV6-Entry-EPHB4 (RC208559, OriGene) was used as template
with the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent). All
primers (Supplementary Table 2) were designed with QuikChange Primer
Design (Agilent) and all constructs verified by Sanger sequencing.
Cell culture, transfection, and activation of EPHB4 receptor
Human dermal lymphatic endothelial cells (LECs) (C-12217, PromoCell)
were cultured in supplemented endothelial growth medium MV2 (C-
22022, PromoCell) containing 50 ng/ml VEGF-C (9199-VC-025, Bio-Techne).
The cells are routinely analyzed by flow cytometric analysis and
immunofluorescent staining: >95% of the cells are CD31 positive and
podoplanin positive. All experiments with LECs were repeated n ≥ 3 with
cells isolated from independent single donors.
The day before transfection 2×105 cells/well were seeded in fibronectin-
coated (F1141, Sigma-Aldrich) 6-well plates. They were then transfected
with 2 µg of the EPHB4 constructs and Viromer Yellow transfection reagent
(VY-01LB-01, Lipocalyx) or 1 µg of the EPHB4 constructs and Lipofectamine
3000 transfection reagent (Life Technologies). Ligand activation of EPHB4
receptor was performed as previously described.2
Immunoprecipitation and western blot
Twenty-four hours post-transfection LECs were harvested in lysis buffer
and immunoprecipitation performed as previously described.2 Immuno-
precipitates were separated by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred to Immobilon-FL PVDF
membranes (Millipore). Membranes were blocked with TBS blocking
solution (Odyssey Blocking Buffer diluted 1:1 in TBS, LI-COR Biosciences)
and incubated with goat antihuman EPHB4 (AF3038, Bio-Techne) and
mouse antiphosphotyrosine (clone 4G10, 05–321, Millipore) antibodies
diluted in TBS blocking solution containing 0.2% Tween 20 (Sigma-Aldrich).
After incubation with IRDye 680RD donkey antigoat IgG (925–68074, LI-
COR Biosciences) and IRDye 800CW donkey antimouse IgG (925–32212, LI-
COR Biosciences) antibodies diluted in TBS blocking solution containing
0.2% Tween 20 (Sigma-Aldrich) and 0.01% SDS (Sigma-Aldrich), mem-
branes were scanned with the Odyssey infrared imaging system (LI-COR
Biosciences).
For the detection of EPHB4 expression levels, after transfection, cell
lysates were subjected to western blotting as above but instead, EPHB4
expression was detected with C-terminal specific mouse anti-DDK (clone
4C5, TA50011, OriGene), and mouse anti-GAPDH (clone 6C5, MAB374,
Millipore) was used as an internal control. Uncropped western blots are
shown in Supplementary Figure 7.
Immunofluorescence and microscopy
Human dermal LECs were seeded on fibronectin-coated glass coverslips
prior to lipofectamine-mediated transfection with EPHB4 variants. After 24
hours transfection, cells were fixed with 3% paraformaldehyde (PFA), then
permeabilized and quenched with 0.2% saponin/50mM NH4CI. Mouse
anti-DDK and goat anti-VE-Cadherin (sc-6458, Santa Cruz Biotechnology)
were used as primary antibodies. Alexafluor488 antimouse (A32766,
Invitrogen) and Alexafluor555 antigoat (A32816, Invitrogen) were used as
fluorophore-conjugated secondary antibodies. All antibody dilutions were
prepared in PBS containing 0.2% (w/v) fish skin gelatin, 0.02% (w/v)
saponin, and 0.02% (w/v) NaN3. DAPI (Sigma-Aldrich) was used for nuclei
detection and VECTASHIELD® (Vector Laboratories) was used as mounting
S. Martin-Almedina et al.
2













medium. Images were taken at 20× magnification with the EVOS™ M5000
imaging system (Thermo Fisher Scientific, Waltham, MA, USA) and
analyzed in GIMP (www.gimp.org).
RESULTS
Novel EPHB4 variants related to fetal hydrops of unknown etiology
Since the first report of two pathogenic EPHB4 missense variants
associated with LRFH,2 four additional cases of fetal hydrops (FH1:
II.2, FH2:II.1, FH4:II.1, and FH5:II.2) and one case presenting with
bilateral pleural effusions (FH3:II.7) with variants in EPHB4 have
come to our attention (Fig. 1a–c). Including other family members,
who carried an EPHB4 variant, a total of seven individuals are
reported all presenting with lymphovenous problems and/or
congenital heart defects (CHD); for full clinical details and
pedigrees see the Supplementary Information, Supplementary
Table 1, and Supplementary Figs. 1, 2.
The two pathogenic variants reported by Martin-Almedina et al.
are located in the intracellular tyrosine kinase domain.2 Of the five
new referrals, four carried missense EPHB4 VUS also located in the
same region (Supplementary Figure 4) and conservation analysis
revealed that all the variants alter highly conserved residues in the
tyrosine kinase domain of EPHB4 (Supplementary Figure 5A). The p.
R744H variant was reported in two unrelated cases (FH1:II.2 and FH2:
II.1) (Table 1) and is located in a highly conserved region in close
proximity to the catalytic loop HRD (His-Arg-Asp), also strongly
conserved in most protein kinases (Supplementary Figure 5B) and
predicted to control the active conformation of the kinase
domain.21,22 FH4:II.1 carried an indel (c.760_761insC) predicted to
cause a frameshift resulting in the premature truncation of the
EPHB4 protein (p.S254Tfs*10), which would lack several functional
domains including the tyrosine kinase domain (Supplementary
Figure 4). None of the variants were reported in gnomAD and in
silico analysis predicts them to be nonfunctional (Table 1).
Novel EPHB4 variants related to a vascular anomaly phenotype
The findings from Amyere et al.6 and Wooderchak-Donahue et al.9
led to the identification in our genetics clinic of two index cases
presenting with familial telangiectasia with novel variants in EPHB4.
There were five affected individuals from two families (VA1 and VA2)
who presented with HHT-like features (Fig. 1d, e). For the full clinical
details see Supplementary Information, Supplementary Table 1, and










Fig. 1 Clinical findings in individuals with EPHB4 variants. (a) Antenatal ultrasound scan (transverse plane) demonstrating bilateral pleural
effusions at gestational week 30+ 4 in FH2:II.1. (b) Baby in the neonatal period with fetal hydrops (GLDUK:II.6). (c) Persistent peripheral
lymphedema in the feet of FH5:II.2 at age 4 years. (d) Capillary malformation in the midline of the neck in VA1:II.2. (e) Multiple telangiectasia
along the vermilion border of the upper lip and the mucous membrane of the lower lip in VA2:II.1 (inside boxed areas). (f) Early onset and
extensive lower limb varicose veins in GLDUK:I.2. (g) GLDUK:II.4 with multiple telangiectasia with a propensity for the vermilion border of the
lips (inside boxed area). (h) Dermatoscopic image of telangiectasia on the left cheek confirming the presence of dilated linear and branching
capillary vessels in GLDUK:II.4.
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stop-gain, p.Q711X, leading to a premature stop codon in the
tyrosine kinase domain (Supplementary Figure 4), and VA2 family
members a missense variant, p.T110P, in the extracellular ligand
binding domain in a highly conserved residue (Supplementary
Figures 4, 5A). None of the variants are in gnomAD and in silico
analysis predicts them to be nonfunctional (Table 1).
Novel EPHB4 variant related to isolated persistent peripheral
primary lymphedema
After the screening of a patient (PL1:II.3) with primary lymphedema
on the primary lymphedema gene panel through South West
Thames Regional Genetic Services, a VUS in EPHB4 was identified. All
three affected family members in PL1 carried this EPHB4 variant and
the main clinical feature was early onset (around age of 2 years)
swelling of the lower limbs. There was no history of fetal hydrops,
CHD, CM, AVM, or telangiectases. Lymphoscintigraphy imaging was
consistent with primary lymphedema (Fig. 2a, b). The full clinical
details and the pedigree are presented in the Supplementary
Information, Supplementary Table 1, and Supplementary Figure 3.
The EPHB4 VUS identified, p.N410K, is located in the extracellular
fibronectin domain (Supplementary Figure 4) in a highly conserved
residue (Supplementary Figure 5A), is not reported in gnomAD, and
in silico analysis predicts it to be nonfunctional (Table 1).
Update on clinical findings in previously published EPHB4-
associated LRFH cases
Since the first report in 2016,2 the two families, GLDUK and
GLDNOR, have been periodically evaluated at the respective
specialist centers. Despite no apparent clinical signs of persistent
peripheral lymphedema, three individuals underwent lymphos-
cintigraphy imaging, which confirmed abnormal lower limb
lymphatic function (Fig. 2c, d, f). Lymphoscintigraphy in the
GLDNOR and GLDUK cases shared features of abnormal lymphatic
drainage via tortuous tracts with superficial rerouting similar to
previous findings in the GLDUK family (Fig. 2e, g).
2 Features
suggestive of venous hypertension contributing to impaired
lymphatic function were also observed. This is in keeping with
the observation of often extensive varicose veins from a young
age in all five adults investigated in the two families (Fig. 1f).
Updated clinical details are given in the Supplementary Informa-
tion, Supplementary Table 1, and Supplementary Figure 1.
At the time of the original publication, none of the individuals in
the GLDUK and GLDNOR families were assessed for telangiectases
or capillary malformations. At a recent visit, GLDUK:III.2 reported
repeated nose bleeds and on further inspection several telangiec-
tases were identified around his mouth. It was also noticed that his
mother (GLDUK:II.4) had multiple, diffuse telangiectases around the
mouth and on her hands (Fig. 1g, h). Both of these individuals
have ASDs (III.2 had multiple ASDs) and neither were hydropic or
had pleural effusions unlike other affected family members. Brain
and spine magnetic resonance images (MRIs) were entirely
normal, no AVMs were identified, and there were no capillary
malformations. No pathogenic variants in the HHT genes (ENG,
ACVRL1, GDF2, and SMAD4) or RASA1 were identified in the exome
data of GLDUK:II.4 so it is highly likely that the EPHB4 variant is
causing the overlapping features in the two.
Analysis of protein expression levels, kinase activity, and
subcellular localization of EPHB4 mutated proteins expressed in
LECs
Functional analysis of the two pathogenic missense variants
originally reported to cause LRFH demonstrated normal EPHB4
protein expression levels but reduced protein activity.2 The
analysis of 4 of the 20 missense variants reported to cause CM-
AVM2 by Amyere et al. showed largely reduced protein expression
levels with EPHB4 protein aggregated in intracellular inclusions.6
These findings led us to carry out a functional classification of the
seven new variants for FH1-FH5, VA1–2, and PL1.
As a reference, the two previously published missense variants,
p.R739Q and p.I782S, were included,2 and missense variant, p.
D802G,5 was included as a representation of the CM-AVM2
phenotype. All three are located in the tyrosine kinase domain of
EPHB4 in highly conserved residues and are predicted to be
pathogenic by in silico analysis (Table 1, Supplementary Figures 4,
5). They are all novel, except p.D802G, which has been reported







GLDUK chr7:100807483-100807483 c.2216G>A R739Q
GLDNOR chr7:100806559-100806559 c.2345T>G I782S
FH1 chr7:100807468-100807468 c.2231G>A R744H
FH2 chr7:100807468-100807468 c.2231G>A R744H
FH3 chr7:100807372-100807372 c.2327G>A S776N
FH4 chr7:100822318-100822318 c.760_761insC S254Tfs*10
FH5 chr7:100805525-100805525 c.2654A>G K885R
VA1 chr7:100807568-100807568 c.2131C>T Q711X
VA2 chr7:100823727-100823727 c.328A>C T110P
CM-AVM2 chr7:100806499-100806499 c.2405A>G D802G
PL1 chr7:100819624-100819624 c.1230C>G N410K
SNP chr7:100807375-100807375 c.2324C>T T775M
SNP chr7:100805535-100805535 c.2644G>A A882T














TKD 35 0.916 Pathogenic - -
TKD 26.5 0.971 Pathogenic - -
TKD 31 0.916 Pathogenic - -
TKD 31 0.916 Pathogenic - -
TKD 29.2 0.749 Pathogenic - -
- - - Pathogenic - -
TKD 24.3 0.769 Pathogenic - -
- 38 - Pathogenic - -
LBD 27.9 0.971 Pathogenic - -
TKD 32 0.971 Pathogenic 0.000004 0
FND 23.2 0.971 Pathogenic - -
TKD 30 0.971 Pathogenic 0.000024 0
TKD 23.5 0.639 Pathogenic 0.001195 3



















Genomic coordinates, nucleotide and protein changes, predicted pathogenicity, and population allele frequencies are summarized. All previously reported
EPHB4 variants for the GLDUK, GLDNOR, and CM-AVM2 cases and EPHB4 variants of uncertain significance (VUS) for the FH1–FH5, VA1–VA2, and PL1 cases are
either not reported in gnomAD databases or their allele frequency is infinitesimal, supporting the argument that they are extremely rare in the general
population, while they are all reported to be pathogenic by all three prediction tools used (CADD, PolyPhen-2, MutationTaster). The three EPHB4 variants
used as controls (SNP) in this study are reported as rare variants (AF < 0.01) in gnomAD databases. Two of them are found in homozygotes and/or are
predicted as pathogenic. GLDUK and GLDNOR published in Martin-Almedina et al.
2 and CM-AVM2 in Yu et al.5
AF allele frequency, CM-AVM capillary malformation–arteriovenous malformation, FH fetal hydrops, FND fibronectin domain, LBD ligand binding domain, PL
primary lymphedema, SNP single-nucleotide polymorphism (likely benign variant), TKD tyrosine kinase domain, VA vascular anomalies.
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once in gnomAD, but is extremely rare (minor allele frequency
[MAF]= 0.000004).
In addition, three variants located in the tyrosine kinase domain
and not reported to be associated with disease were identified in
gnomAD and included as controls. Two of the variants have been
reported in homozygotes, they all had a low MAF
(0.000024–0.006) and whilst we suspect them to be benign
variants, in silico analysis predicts them to be pathogenic (Table 1,
Supplementary Figures 4, 5A).
We generated mammalian expression vectors for the wild-type
(WT) form of EPHB4 and for each of the 13 variants listed in
Table 1 by site-directed mutagenesis. The constructs were
transfected into LECs and the effects of the variants on EPHB4
protein expression levels were analyzed by western blot. Most of
the variants tested resulted in expression levels comparable with
the WT protein (Fig. 3a). However, the three variants, p.T110P, p.
N410K, and p.D802G, showed reduced expression of protein, and
what seems to be a shorter protein (compared with the predicted
108-kDa full-size protein). Variants p.Q711X and p.S254Tfs*10
could not be detected with the C-terminal specific antibody,
indicating a loss of full-size protein expression. The in silico
prediction from MutationTaster suggests the two variants lead to
nonsense-mediated decay (NMD) due to the introduction of
premature stop codons.
To investigate the possible impact of the variants on EPHB4
function, the tyrosine kinase activity of the receptor was
analyzed by immunoprecipitation and western blot after
EphrinB2 stimulation. We also included the three control
variants in this analysis. Stimulation with preclustered EphrinB2
(EphrinB2-Fc) for 30 minutes increased the tyrosine phosphor-
ylation level of the receptor after its binding in the WT form
while tyrosine phosphorylation was reduced or not detected
for most variants (Fig. 3b). The three control variants displayed
tyrosine phosphorylation activity after EphrinB2 treatment; so
did one VUS (p.K885R).
Immunofluorescence studies were performed to investigate the
subcellular localization of the generated variants. Exogenous
EPHB4 expression was detected with an anti-DDK antibody, while
VE-cadherin expression was used as a marker of cell–cell
membrane contact. Five of the variants investigated were
detected in the cell membrane, confirmed by the localization in
proximity to VE-cadherin, showing a similar expression localization
pattern to the WT protein. On the other hand, the three variants, p.
T110P, p.N410K, and p.D802G, showed absent or much reduced
membrane localization and a distinct intracellular expression
pattern. In some cells, increased reticular staining and/or
intracellular aggregates that could be accumulations of misfolded
proteins were detected when transfecting these three variants
(Fig. 3c). A summary of our interpretation on the effect of the
EPHB4 variants regarding the expression levels, kinase activity, and
subcellular localization obtained from the functional assays is
shown in Supplementary Table 3.
DISCUSSION
Since the initial reports of germline variants in EPHB4 associated
with a disease phenotype,2,4–9 new cases with EPHB4 VUS have
come to our attention from several clinicians looking for additional
evidence to confirm diagnosis. To verify the pathogenicity of all
the new variants, we investigated protein expression levels,
tyrosine kinase activity, and subcellular localization of the EPHB4




a b c d e f hg
Family PL1 PL1 GLDNOR GLDNOR GLDUK GLDUK GLDUK
Individual II.3 III.1 II.2 II.3 II.4 II.2 I.2
Lower limb Right Left Right Left Right Left Right Left Right Left Right Left Right Left Normal values
Tracer retention in foot at 2hrs (%) 91.5 91.1 83 96.9 - - - - 70 71 82.3 87.7 88 97 <80
Uptake in ilioinguinal nodes at 2hrs (%) 0.5 4.6 18.7 2.9 borderline reduced normal normal 20 17 2.8 1.3 0.8 0.2 >8
EPHB4 variant c.1230C>G c.1230C>G c.2345T>G c.2345T>G c.2216G>A c.2216G>A c.2216G>A
Predicted protein change p.N410K p.N410K p.I782S p.I782S p.R739Q p.R739Q p.R739Q
Sex F F F F F F M
Age at time of scan 16 6 37 37 24 24 42
Fig. 2 Imaging of the lymphatic system in individuals with EPHB4 variants. Anterior view of lower limb lymphoscintigraphy 2 hours after
injection. Quantification figures 2 hours postinjection are given where available. Values for an individual with a normal lymphatic system are
given on the right. Any values deviating from the normal values, indicating abnormal lymphatic drainage, are highlighted in red. Genetic
variants and predicted protein changes are also shown. Refer to the Supplementary Information for a detailed description of the lymph scans.
(a) PL1:II.3 demonstrated abnormal lymphatic drainage in both legs with evidence of bilateral deep rerouting via the popliteal lymph nodes
(arrows). (b) PL1:III.1 has abnormal drainage, possibly due to deep rerouting but the popliteal lymph nodes are not visible in this scan. (c)
GLDNOR:II.2 has multiple tortuous lymphatic tracts in the lower limbs. Superficial rerouting of tracer is apparent in the calves. (d) GLDNOR:II.3
has tortuous lower limb lymphatic tracts and superficial rerouting of tracer is present around the ankles and calves. (e) The lower limb
lymphatic tracts in GLDUK:II.4 are tortuous and superficial rerouting is seen within the calves (dark shading, arrowheads). (f) GLDUK:II.2 has
symmetrical impairment of lymphatic drainage within both lower limbs. The main lymphatic tracts are tortuous. (g) GLDUK:I.2 has superficial
rerouting of tracer in the right leg (arrowhead) and deep rerouting via the right popliteal lymph nodes. Lymphatic tracts in the right limb are
tortuous. There is markedly reduced lymphatic transport in the left limb with no visible uptake of tracer in the left inguinal lymph nodes. (h)
Unaffected subject with symmetrical transport of radionuclide tracer from injection sites in the feet up to the inguinal lymph nodes via main
lymphatic vessels. The black dot in (f) is the orientation marker. F female, M male.
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investigation resulted in a reduction or total absence of EPHB4
kinase activity, due to the presence of a dysfunctional receptor or
total loss of protein expression. Thus, for most variants we were
able to report a damaging effect on the protein function to the
clinicians, suggesting that the VUS was pathogenic and causative
of the disease. However, the p.K885R variant in family FH5
performed similarly to the WT protein in our functional assays.
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conclude it was the cause of the LRFH in this family; therefore,
more extensive functional work must be done to confirm its
pathogenicity.
We phenotypically describe eight new families with variable
lymphatic and vascular phenotypes associated with novel EPHB4
variants (summarized in Table 2) and provide a more detailed clinical
report for the two families first published in 2016. Until now, our
understanding has pointed toward the existence of two phenotypi-
cally differentiated autosomal dominantly inherited disease entities
caused by germline variants in EPHB4: LRFH and CM-AVM2. Based on
the evaluation of the new families, individuals in families VA1 and VA2
could be classified under the umbrella of CM-AVM2 as their
presentation is similar to that given by Wooderchak-Donahue et al.,
who reported a mucocutaneous telangiectasia in a series of atypical
HHT cases with EPHB4 variants.9
Five of the new cases were more difficult to interpret. They had
fetal hydrops (FH1–FH3 and FH5) or pleural effusions (FH4), which
were suspected to be lymphatic-related in FH1 and FH5 as they
had chylous (“milky”) fluid drained postnatally. However, the lack
of clinical information for the other cases does not allow us to
conclude whether lymphatic dysfunction is the source of the fetal
hydrops phenotype.
Of particular significance is the discovery of intrafamilial
overlapping phenotypes with individuals presenting with features
of both LRFH and CM-AVM2 (Table 2). An increasing number of
allelic conditions have now been shown to have features of two
different phenotypes in the same individual or family—the Janus
(after the ancient Roman god with two faces) or dual
phenotype.23,24 Furthermore, overlapping lymphatic and vascular
features have previously been reported in patients with RASA1-
associated CM-AVM type 1.25
Three individuals from the PL1 family presented with peripheral
primary lymphedema but no history of fetal hydrops or ASD. The
onset of lymphedema was around the age of 2 years and the
lymphoscintigraphy was distinct from those of the LRFH families.
PL1 also differs from the CM-AVM2 cases as there were no CM or
AVMs. This is the first family to be described with just primary
lymphedema and a likely pathogenic variant in EPHB4. Either early
onset isolated peripheral primary lymphedema is a new separate
entity (in addition to LRFH and CM-AVM2) in the increasing family
of EPHB4-associated phenotypes, or, based on the proposed
disease mechanism elucidated through our functional analysis,
the CM-AVM2 phenotype spectrum needs expanding to include
primary lymphedema.
Our results show different possible molecular disease mechan-
isms associated with EPHB4 pathogenesis and highlight the
importance of further research into the functional and clinical
consequences of the disruption of the EPHB4 forward and reverse
signaling cascades. For some variants, we have shown that the
EPHB4 mutant protein is expressed and presented on the
membrane of LECs, but that tyrosine kinase activity is reduced,
presumably altering the forward signaling (Fig. 3d, left). Reverse
signaling might be unaffected although this was not investigated
here. The reduced forward signaling could be due to an
antimorphic disease mechanism with a dominant negative effect
of the EPHB4 mutant on the WT protein activity. This dominant
negative disease mechanism has been suggested for some
VEGFR3 variants associated with primary lymphedema.26 The
variants in this category predominantly associated with LRFH with
fetal hydrops, lymphovenous abnormalities, and ASD, some with
very mild symptoms (e.g., FH3).
For other variants, we detected a loss of EPHB4 protein,
probably due to either nonsense-mediated messenger RNA
(mRNA) decay or protein degradation. Any EPHB4 mutant protein
detected was of a shorter size and was trapped intracellularly,
which could be a sign of the protein undergoing degradation.
These EPHB4 mutants are most likely amorphic, acting as null
alleles (Fig. 3d, right). Lower EPHB4 receptor levels will lead to an
imbalance in the ratio of EphrinB2 ligand to EPHB4 receptor,
which promotes cell dysfunction in normal microvascular
endothelial cells.27 Variants in this category predominantly
associated with CM-AVM2, but there were exceptions (e.g., the
PL1 family). Bidirectional Eph-Ephrin signaling is complex and we
can only speculate on how downstream forward or reverse
signaling is affected by the EPHB4 variants as this was not
investigated in this study. The existence of receptor–ligand
oligomerization and bidirectional endocytosis of receptor–ligand
complexes add another level of intricacy, which supports the need
for more research into the field to fully understand the
contribution of both forward and reverse signaling to the
arteriovenous and lymphovenous compartments.
Further studies are also needed to explain why the phenotype
within families can be so variable. Several authors have suggested
that a postzygotic de novo variant in the other allele (“second hit
hypothesis”) would be required for the development of the focal
lesions associated with the CM-AVM2 disease phenotype.6–8 This
mechanism has been shown for other hereditary multifocal vascular
malformations such as RASA1-associated CM-AVM1.28–30 However,
variable expression of the disease phenotype could also be due to
genetic modifiers or polygenic inheritance, therefore, it is necessary to
understand whether one or two EPHB4 null alleles will lead to disease.
In conclusion, several reports have shown that monoallelic
EPHB4 variants can cause a spectrum of arteriovenous and
lymphovenous disorders, but our findings add more complexity
to this. We introduce a possible new phenotype, dominant
primary lymphedema, which showed no overlap with LRFH and
CM-AVM2 as we currently understand them. However, with the
observation of overlapping phenotypes between LRFH and CM-
AVM2, the EPHB4-associated disease classifications might need a
major revision. Regardless, a change of clinical practice is required
as cases thought to be CM-AVM2 should undergo echocardio-
graphy, while cases thought to be LRFH should also undergo
Fig. 3 In vitro functional characterization of EPHB4 VUS after transfection into lymphatic endothelial cells (LECs). (a) Western blot analysis
of EPHB4 expression detected with anti-DDK antibody and GAPDH used as a loading control. The position of molecular mass markers (in kDa)
is indicated to the right of the gel. (b) Effect of EPHB4 variants on EPHB4 tyrosine phosphorylation in LECs after EphrinB2 stimulation with 1 μg/
ml clustered Ephrin B2/Fc (EB2/Fc) or Fc alone. Receptor phosphorylation was analyzed by immunoprecipitation with anti-DDK antibody and
western blotting using anti-p-tyrosine (upper panel) and EPHB4 (lower panel) antibodies. (c) Subcellular localization of EPHB4 variants. EPHB4
receptor was visualized with anti-DDK antibody (green), cell–cell contact with anti-VE-cadherin antibody (red) and nuclei with DAPI (blue).
Membrane localization of the receptor is marked with arrowheads, cytoplasmic reticular localization with an asterisk, and intracellular
aggregates with arrows. Images taken at 20× magnification with an EVOS™ M5000 imaging system. Scale bar 125 µm. For (a–c), one
representative of ≥3 experiments is shown. (d) Model for potential EPHB4 molecular disease mechanisms. Left: Some mutant receptors were
present in the membrane, lacking tyrosine activity. Whether this leads to EPHB4 haploinsufficiency or a dominant negative effect of the
mutant EPHB4 was not tested in this study. Most variants fitting with this model were cases with a lymphatic-related fetal hydrops (LRFH)
phenotype. Right: Other mutant receptors were sequestered into intracellular aggregates, leading to a loss-of-function disease mechanism.
Most variants fitting with this model were cases with a CM-AVM2 phenotype. Bidirectional Eph-Ephrin signaling is complex with the existence
of receptor–ligand oligomerization and bidirectional endocytosis of receptor–ligand complexes and we can only speculate on how forward or
reverse signaling would be affected. MUT mutant EPHB4 receptor, WT wild-type EPHB4 receptor.
S. Martin-Almedina et al.
7
Genetics in Medicine _#####################_
careful skin examination and consideration of brain and spine MRI
to check for arteriovenous malformations. Furthermore, EPHB4
variant pathogenicity was demonstrated in this study for six of the
seven novel VUS investigated and highlights the usefulness of
protein expression and subcellular localization studies to predict
the pathogenesis of VUS. With NGS as a routine method for the
diagnosis of inherited disorders, the detection rate for rare and
novel variants is growing and inferring the pathogenicity of the
identified variants can be challenging. Therefore, as suggested by
the American College of Medical Genetics and Genomics/
Association for Molecular Pathology (ACMG/AMP) guidelines,31 a
comparable approach is essential for other genes/diseases to
maximize diagnostic rates. Our study also highlights different
EPHB4-related disease mechanisms; however, further research is
necessary to expand our knowledge on how they operate at a
cellular and molecular level to fully understand the intricate EPHB4
clinical enigma.
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Table 2. Clinical summary.










I.2 M 60 Yes Yes Yes
II.2 F 35 Yes Yes (Yes) Yes
II.4 F 29 Yes (Yes) Yes Yes
II.6 M ND 21d Yes Normal
II.7 F IUD 26wks Yes Normal
III.1 M 13 Yes Yes
III.2 M 9 Yes Yes
II.2a F 42 ? Normal (Yes) Yes
II.3a F 42 ? Yes (Yes) Yes
III.5 M ND 1.5d Yes Yes
III.9 M 11 Yes Yes
FH1 II.2 M ND 36d Yes Yes R744H
FH2 II.1 F ND 9wk Yes Yes R744H
FH3 II.7 F only PE Normal S776N
FH4 II.1 M IUD? Yes Yes b S254Tfs*10
I.2 F 40 Normal Yes
II.1 F 8 ? Normal
II.2 M 4 Yes Yes Yes
I.2 F 44 Yes
II.1 F 17 Yes
II.2 F 16 Yes
I.1 M 54 Yes
II.1 M 14 Yes
II.2 F Yes
II.3 F 14 Yes













Overview of the phenotype of the eight new index cases and affected family members with an EPHB4 VUS (FH1–FH5, VA1–VA2, and PL1) included in this
study. Clinical details for the EPHB4 index cases and affected family members previously reported by Martin-Almedina et al. (GLDUK and GLDNOR)
2 have been
updated and included for comparison. Telangiectases are indicated in teal. Features originally described as associated with lymphatic-related fetal hydrops
(LRFH) are indicated with a pale yellow. The lymphedema observed in PL1 is different on lymphoscintigraphy to that of individuals from the GLDUK and
GLDNOR families, thus a darker shading has been used to indicate it. Refer to the Supplementary Information and Supplementary Table 1 for detailed clinical
description of each case. “?” in the fetal hydrops column indicates that there were hydropic features at birth. “Normal” in the congenital heart defect column
indicates that a normal echocardiogram was obtained. “(Yes)” in the persistent peripheral lymphedema column indicates that the individual is clinically
normal, but abnormal lymphatic drainage was demonstrated on lymphoscintigraphy. Blank fields indicate the relevant procedure was not carried out or the
information was not available.
F female, FH fetal hydrops, GLD generalized lymphatic dysplasia, IUD intrauterine death, M male, ND neonatal death, PE pleural effusions, PL primary
lymphedema, VA vascular anomaly.
aMonozygotic twins.
bThe type of EPHB4 variant suggests this could be a capillary malformation–arteriovenous malformation 2 (CM-AVM2) case, but telangiectasia was not
confirmed.
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